Skip to main content

Advertisement

SpringerLink
Log in

Clinical and Economic Issues in the Treatment of Advanced Breast Cancer with Bisphosphonates

  • Leading Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

An ideal palliative therapy for bone metastases would successfully reduce skeletal complications in several thousands of breast cancer patients. Second- and third-generation bisphosphonates are effective in reducing the overall skeletal complication rate and the time to first skeletal complication.

Nevertheless, not enough evidence supports their benefit on quality of life. Furthermore, bisphosphonates are expensive (up to $US775 per month, 2002 value) and cost-effectiveness evaluations have been limited to pamidronate (pamidronic acid). In economic evaluations of pamidronate, resulting incremental dollar per quality-adjusted life year gained ranged from cost savings to $US108 000 per quality-adjusted life year. The data were quite sensitive to quality-of-life estimates and country-specific cost values.

Because of the wide range of the cost-effectiveness ratio, it is uncertain whether the universal prescription of bisphosphonates in this setting represents an efficient use of healthcare resources. Probably, country- and drug-specific policies might increase the efficiency of this treatment. Further outcomes research is required to assess these agents more fully.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV
Table V

Similar content being viewed by others

References

  1. Jemal A, Thomas A, Murray T, et al. Cancer statistics, 2002. CA Cancer J Clin 2002; 52: 23–47

    Article  PubMed  Google Scholar 

  2. Traina A, Cusimano R, Liquori M, et al. Breast cancer registry in Palermo and its Province: incidence in 1999. Ann N Y Acad Sci 2002; 963: 85–90

    Article  PubMed  CAS  Google Scholar 

  3. Italian Ministry of Health, [online]. Available from URL: http://www.sanita.it/sdo/dati/aggregati [Accessed 2002 July 30]

  4. Richards MA, Braysher S, Gregory WM, et al. Advanced breast cancer: use of resources and cost implications. Br J Cancer 1993; 67: 856–60

    Article  PubMed  CAS  Google Scholar 

  5. Reszxka AA, Halasy-Nagy JM, Masarachia PJ, et al. Bisphosphonates act directly on the osteoclast to induce capase cleavage of mst1 kinase during apoptosis: a link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase. J Biol Chem 1999; 274: 34967–73

    Article  Google Scholar 

  6. Liberato NL, Marchetti M, Tamburlini A, et al. Pamidronate in advanced breast cancer: a cost-effectiveness analysis [abstract]. Eur J Cancer 2000; 36Suppl 3: S4

    Google Scholar 

  7. Dranitsaris G, Hsu T. Cost utility analysis of prophylactic pamidronate for the prevention of skeletal events in patients with advanced breast cancer. Support Care Cancer 1999; 7: 271–9

    Article  PubMed  CAS  Google Scholar 

  8. Hillner BE, Weeks JC, Desch CE, et al. Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol 2000; 18: 72–9

    PubMed  CAS  Google Scholar 

  9. Guignard E, Dardenne J, Pele A. Economic assessment of clodronate in the preventive treatment of bone resorption in patients with metastatic breast cancer [abstract]. Eur J Cancer 1997; 33Suppl. 9: 25

    Article  Google Scholar 

  10. Coleman RE, Smith P, Rubens RD. Clinical course and prognostic factors following recurrence from breast cancer. Cancer 1998; 77: 336–40

    Article  CAS  Google Scholar 

  11. Kristensen B, Ejlertsen B, Mouridsen HT, et al. Survival in breast cancer patients after the first episode of hypercalcaemia. J Intern Med 1998; 244: 189–98

    Article  PubMed  CAS  Google Scholar 

  12. Scheid V, Buzdar AU, Smith TL, et al. Clinical course of breast cancer patients with osseous metastasis treated with combination chemotherapy. Cancer 1986; 58: 2589–93

    Article  PubMed  CAS  Google Scholar 

  13. Hurst M, Noble S. Clodronate: a review of its use in breast cancer. Drugs Aging 1999; 15: 143–67

    Article  PubMed  CAS  Google Scholar 

  14. Elomaa I, Blomqvist C, Porkka L, et al. Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases. Lancet 1983; I: 146–9

    Article  Google Scholar 

  15. Ernst DE, MacDonald RN, Paterson AHG, et al. A double-blind cross-over trial of IV clodronate in metastatic bone pain. J Pain Symptom Manage 1992; 7: 4–11

    Article  PubMed  CAS  Google Scholar 

  16. Robertson AG, Reed NS, Ralston SH. Effect of oral clodronate on metastatic bone pain: a double-blind, placebo-controlled study. J Clin Oncol 1995; 13: 2427–30

    PubMed  CAS  Google Scholar 

  17. Paterson AHG, Powles TJ, Kanis JA, et al. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993; 11: 59–65

    PubMed  CAS  Google Scholar 

  18. Kristensen B, Ejlertsen B, Groenvold M, et al. Oral clodronate in breast cancer patients with bone metastases: a randomized study. J Intern Med 1999; 246: 67–74

    Article  PubMed  CAS  Google Scholar 

  19. Tubiana-Hulin M, Beuzeboc P, Mauriac L, et al. Essai comparatif randomisè en double aveugle clodronate oral 1600 mg/j versus placebo chez des patientes avec metatases osseuses de cancer du sein. Bull Cancer 2001; 88: 701–7

    PubMed  CAS  Google Scholar 

  20. Coleman RE, Woll PJ, Miles M, et al. Treatment of bone metastases from breast cancer with (3-amino-1-hydroxypropylidene)-l,l-biphosphonate (APD). Br J Cancer 1988; 58: 621–5

    Article  PubMed  CAS  Google Scholar 

  21. Thiebaud D, Leyvraz S, von Fliedner V, et al. Treatment of bone metastases from breast cancer and myeloma with pamidronate. Eur J Cancer 1991; 27: 37–41

    Article  PubMed  CAS  Google Scholar 

  22. Glover D, Lipton A, Kller A, et al. Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer: a dose-seeking study. Cancer 1994; 74: 2949–55

    Article  PubMed  CAS  Google Scholar 

  23. Tyrrell CJ, on behalf of the Aredia Multinational Cooperative Group. Role of pamidronate in the management of bone metastases from breast cancer: results of a non-comparative multi-center phase II trial. Ann Oncol 1994; 5Suppl. 7: S37–40

    PubMed  Google Scholar 

  24. Purohit OP, Anthony C, Rastone CR, et al. High-dose intravenous pamidronate for metastatic bone pain. Br J Cancer 1996; 70: 554–8

    Article  Google Scholar 

  25. Cascinu S, Casadei V, Del Ferro E, et al. Pamidronate in patients with painful bone metastases, who failed initial treatment with hormones and/or chemotherapy. J Support Care Cancer 1996; 4: 31–3

    Article  CAS  Google Scholar 

  26. Vinholes J, Purohit OP, Eastell R, et al. Double-blind randomised trial of pamidronate (Aredia) for the palliative treatment of metastatic bone disease [abstract]. Proc Am Soc Clin Oncol 1996; 15: 528

    Google Scholar 

  27. Coleman RE, Purohit OP, Vinholes JJ, et al. High-dose pamidronate: clinical and biochemical effects in metastatic bone disease. Cancer 1997; 80Suppl. 8: 1686–90

    Article  PubMed  CAS  Google Scholar 

  28. Van Holten-Verzantvoort ATM, Kroon HM, Bijvoet OLM, et al. Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol 1993; 11: 491–8

    PubMed  Google Scholar 

  29. Conte PF, Latreille J, Mauriac L, et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. J Clin Oncol 1996; 14: 2552–9

    PubMed  CAS  Google Scholar 

  30. Hortobagyi GN, Theriault RL, Lipton A, et al. Long-term prevention of skeletal complications in metastatic breast cancer patients with pamidronate. J Clin Oncol 1998; 16: 2038–44

    PubMed  CAS  Google Scholar 

  31. Holtburn R, Gundersen S, Ryden S, et al. Efficacy of pamidronate in breast cancer with bone metastases: a randomized, double-blind placebo-controlled multicenter study. Anticancer Res 1999; 19: 3383–92

    Google Scholar 

  32. Theriault RL, Lipton A, Hortobagyi GN, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. J Clin Oncol 1999; 17: 846–54

    PubMed  CAS  Google Scholar 

  33. Hortobagyi GN, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 1996; 335: 1785–91

    Article  PubMed  CAS  Google Scholar 

  34. Green JR, Muller K, Jaeggi KA. Preclinical pharmacology of CGP 42′446: a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 1994; 9: 745–50

    Article  PubMed  CAS  Google Scholar 

  35. Berenson JR, Vescio R, Henick K, et al. A phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease. Cancer 2001; 91: 144–54

    Article  PubMed  CAS  Google Scholar 

  36. Berenson JR, Vescio R, Rosen LS, et al. A phase I, dos-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone lesions. Clin Cancer Res 2001; 7: 748–85

    Google Scholar 

  37. Berenson JR, Rosen LS, Howell A, et al. Zoledronic acid reduces skeletal related events in patients with osteolytic metastases: a double-blind, randomized, dose-response study. Cancer 2001; 91: 1191–200

    Article  PubMed  CAS  Google Scholar 

  38. Rosen LS, Gordon D, Antonio BS, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a pase III, double blind, comparative trial. Cancer J 2001; 7: 377–87

    PubMed  CAS  Google Scholar 

  39. Coleman RE, Purohit OP, Black C, et al. Double-blind, randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease. Ann Oncol 1999; 10: 311–6

    Article  PubMed  CAS  Google Scholar 

  40. Pavlakis N, Stockler M. Bisphosphonates for breast cancer. Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 1. Oxford: Update Software, 2002: CD003474

    Google Scholar 

  41. Diel IJ, Solomayer EF, Costa SD, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998; 339: 357–63

    Article  PubMed  CAS  Google Scholar 

  42. Kanis JA, Powels T, Paterson AHG, et al. Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone 1996; 19: 663–7

    Article  PubMed  CAS  Google Scholar 

  43. Saarto T, Blomqvist C, Virkunnen P, et al. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomised controlled trial. J Clin Oncol 2001; 19: 10–7

    PubMed  CAS  Google Scholar 

  44. Cancer Care Ontario Practice Guidelines Initiative. Use of bisphosphonates in women with breast cancer [online]. Available from URL: http://www.ccopebc.ca/guidelines/bre/fulll_ll.pdf [Accessed 2003 May 23]

  45. Hillner BE, Ingle JN, Berenson JR, et al. American Society of Clinical Oncology guidelines on the role of bisphosphonate in breast cancer. J Clin Oncol 2000; 18: 1378–91

    PubMed  CAS  Google Scholar 

  46. BC Cancer Agency. [online]. Available from URL: http://www.bccancer.bc.ca/HPI/CancerManagementGuidelines/Breast/Management/MetastaticDisease.htm [Accessed 2003 July 30]

  47. The Breast Specialty Group of the British association of Surgical Oncology. The management of metastatic bone disease in the United Kingdom. Eur J Surg Oncol 1999; 25(1): 3–23

    Article  Google Scholar 

  48. Tengs TO, Wallace A. One-thousand health-related quality-of-life estimates. Med Care 2000; 38: 583–637

    Article  PubMed  CAS  Google Scholar 

  49. Goossens M, Vlaeyen J, Rutten-van Molken M, et al. Patient utilities in chronic muscolosketeltal pain: how useful is the standard gamble method? Pain 1999; 80: 365–75

    Article  PubMed  CAS  Google Scholar 

  50. Lenert LA, Cher DJ, Goldstein MK, et al. The effect of search procedures on utility elicitations. Med Decis Making 1998; 18: 76–83

    Article  PubMed  CAS  Google Scholar 

  51. Wong R, Wiffen PJ. Biphosphonates for the relief of pain secondary to bone metastases. Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 2. Oxford: Update Software 2002: CD002068

    Google Scholar 

  52. Siris E, Hymann G, Canfield E. Effects of dichloromethylene diphosphonate in women with breast carcinoma metastatic to the skeleton. Am J Med 1983; 74: 401–6

    Article  PubMed  CAS  Google Scholar 

  53. Van Holten-Verzantvoort A, Zwinderman A, Aaronson N, et al. The effects of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer. Eur J Cancer 1991; 27: 544–9

    Article  PubMed  Google Scholar 

  54. Whittington R, Faulds D. Hormone replacement therapy: II. a pharmacoeconomic appraisal of its role in the prevention of postmenopausal osteoporosis and ischaemic heart disease. Pharmacoeconomics 1994; 5: 513–54

    Article  PubMed  CAS  Google Scholar 

  55. Iglesias CP, Torgerson DJ, Bearne A, et al. The cost utility of bisphosphonate treatment in established osteoporosis. QJM 2002; 95: 305–11

    Article  PubMed  CAS  Google Scholar 

  56. Salkeld G, Cameron ID, Cumming RG, et al. Quality of life related to fear of falling and hip fracture in older women: a time trade off study. BMJ 2000; 320: 241–6

    Article  Google Scholar 

  57. Dolan P, Torgerson D, Kakarlapudi TK. Health-related quality of life of Colles’ fracture patients. Osteoporos Int 1999; 9: 196–9

    Article  PubMed  CAS  Google Scholar 

  58. de Koning HJ, van Ineveld BM, de Haes JC, et al. Advanced breast cancer and its prevention by screening. Br J Cancer 1992; 65: 950–5

    Article  PubMed  Google Scholar 

  59. Gessner U, Koeberle D, Thuerlimann B, et al. Economic analysis of terminal care for patients with malignant osteolytic bone disease and pain treated with pamidronate. Support Care Cancer 2000; 8: 115–22

    Article  PubMed  CAS  Google Scholar 

  60. Martin DK, Pater JL, Singer PA. Priority setting decisions for new cancer drugs: a qualitative case study. Lancet 2001; 358: 1676–81

    Article  PubMed  CAS  Google Scholar 

  61. Biermann WA, Cantor RI, Fellin FM, et al. An evaluation of the potential cost reductions resulting from the use of clodronate in the treatment of metastatic carcinoma of the breast to bone. Bone 1991; 12Suppl. 1: S37–42

    Article  PubMed  Google Scholar 

  62. Beusterien KM, Hill MC, Ackerman SJ, et al. The impact of pamidronate on inpatient and outpatient services among metastatic breast cancer patients. Support Care Cancer 2001; 9: 169–76

    Article  PubMed  CAS  Google Scholar 

  63. DesHarnais Castel L, Bajwa K, Markle JP, et al. A microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone disease. Support Care Cancer 2001; 9: 545–51

    Article  PubMed  CAS  Google Scholar 

  64. Orlewska E. Comparison of costs and effects of prophylactic pamidronate for the prevention of skeletal related events in patients with advanced breast cancer in Poland (cost-effectiveness and cost-utility analysis) [abstract]. Value Health 2000; 3: 351

    Article  Google Scholar 

  65. Dranitsaris G. Pamidronate for the prevention of skeletal-related events in multiple myeloma: what does the public think it is worth? Int J Technol Assess Health Care 1999; 15: 108–22

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this manuscript. The authors have no conflicts of interest that are directly relevant to the content of this manuscript.

Author information

Authors and Affiliations

  1. Division of Internal Medicine, Civil Hospital, Via Volturno, 14, Voghera, 27058, Italy

    Nicola Lucio Liberato

  2. Medical Informatics Laboratory, IRCCS S. Matteo Hospital, Pavia, Italy

    Monia Marchetti & Giovanni Barosi

Authors
  1. Nicola Lucio Liberato
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Monia Marchetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Giovanni Barosi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nicola Lucio Liberato.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Liberato, N.L., Marchetti, M. & Barosi, G. Clinical and Economic Issues in the Treatment of Advanced Breast Cancer with Bisphosphonates. Drugs Aging 20, 631–642 (2003). https://doi.org/10.2165/00002512-200320090-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200320090-00001

Keywords

Search

Navigation